印度的幹細胞治療成果(成功案例)：幹細胞+Liberation治療(CCSVI)

幹細胞，就不用我多說，是解決神經系統受損的終極法寶，今日於最新的加拿大消息報導了一位加拿大女士至印度進行了實驗性幹細胞手術後行動力因此恢復，附上原報導內容如下：

一位從加拿大薩斯喀徹溫省的MS病患遠赴印度做了實驗性的幹細胞療法，主要是由加拿大溫尼伯的一家公司[Regenetek Research]的CEO徵求MS病患去印度施行這樣的手術(印度已經核可)。這手術包含靜脈擴張和幹細胞治療。該CEO也是這個研究的領導人，但是有些病患質疑該CEO的身分而且病人術後的聯繫關懷沒有做好。

A multiple sclerosis patient from Saskatchewan who travelled to India to undergo an experimental stem cell treatment is defending the Winnipeg company that recruited her for the therapy and study, which some have called into question.

Regenetek Research has been under scrutiny following media reports this week about its CEO, Doug Broeska.

Broeska had recruited MS patients to take part in the experimental and expensive study, which was administered in India, involving stem cell injections combined with so-called liberation therapy, which involves the widening of veins in the neck.

He was, until recently, also the principal researcher for the study related to the treatment.
However, some patients have questioned Broeska's qualifications as a researcher. As well, some say the therapy did not work for them, and they were not receive proper followup.

• MS patients question credentials of Winnipeg man involved in stem cell therapy

Other patients, like Linda Friesen of Tisdale, Sask., reported having success with the therapy.
"I am shocked right now. I am surprised in what has been said," she told CBC News when asked about the latest allegations.
Friesen said she used to rely on a wheelchair because of her MS and injuries from a car accident, but she left that wheelchair behind at the hospital in India after undergoing the experimental treatment — which cost her $34,000 US — in 2013.
"It's so amazing to have this opportunity to be part of the research," she said in a promotional video produced by Regenetek.

Friesen told CBC News that the company has paid her to help other MS patients in Saskatchewan with their paperwork.
另一位病患 Linda Friesen 則被報導是一個成功的案例。
"聽到那個質疑讓我很震驚"，她過去需要倚賴輪椅(因為MS和一場車禍)，但是在2013年去了印度花了3萬4千美元做這個手術之後，就不需要輪椅了。能參與這個研究很棒。

Regenetek responds

In a statement issued Thursday, Regenetek Research says its stands behind its role in the stem cell therapy study, "namely as researchers tracking participant progress following medical treatment, with such medical treatment having been provided by third-party medical practitioners located in India.

• Winnipeg firm Regenetek issues statement explaining role in MS study

"Regenetek Research and its researchers do not provide medical treatment in connection with the clinical study," the company's statement reads in part.
"Further, the study was never intended to replace other medical treatment and individuals were directed to stay in contact with their treating physicians. We are scientists simply tracking the progress of participants who have chosen to attempt innovative therapy options and to have their results noted by us for scientific study."

Regenetek公司的聲明全文中的一部分如下：“Regenetek及其研究人員不提供治療與臨床研究”。
  “此外，這項研究是從來沒有打算取代其他的治療方式，而每個病患需要和他們的手術醫師保持聯繫。我們科學家只是簡單地追蹤選擇這些創新治療方式手術後的進展，並做一註記。“

Winnipeg-based Regenetek Research issued a statement Thursday in response to media reports about Doug Broeska, who had recruited MS patients to take part in the experimental and expensive study involving stem cell injections combined with so-called liberation therapy. (CBC)

Last month, the ethics committee with the hospital in India where the treatment was being performed ordered Broeska to step down as principal investigator, saying his lack of credentials and medical followup "violated international ethical standards."
Broeska had stated on a LinkedIn profile that he has a PhD from the University of Manitoba, but the university confirmed that neither a Doug Broeska nor a Henry Douglas Broeska graduated from there. The profile has since been removed from the site.
The International Cellular Medicine Society and the College of Physicians and Surgeons of Manitoba both said they have no record of Broeska as a member.
Broeska has not responded to requests from CBC News for an interview. The company's statement was not signed by him, and it does not directly address specific questions about his credentials.
Broeska has defended his qualifications to another media outlet and in emails to patients.
In one message, obtained by CBC News, he told a patient that his credentials are sound and he is "competent to perform research of this type."

Experts concerned about fallout

Meanwhile, some in the scientific community say they're worried that the fallout from this and other controversies could result in confusion about stem cell research as a whole.
Dr. Duncan Stewart of the Ottawa Hospital Research Institute, which is conducting research on using genetically enhanced stem cells to repair damaged heart muscle, said the field is in its early days and has tremendous promise.
"It only takes one high-profile significant problem to make everyone very nervous," he said.
Tim Caulfield, the Canada Research Chair in Health Law and Policy at the University of Alberta, agrees.
"That's a really good example of how the availability of these treatments, marketing of these treatments, can lead people to believe stem cell therapy is much further along than it really is," he said.
The Canadian Stem Cell Foundation says it wants the federal government to invest $50 million in stem-cell research in each of the next 10 years.
It also wants Ottawa to streamline the process for clinical trials in this country "so that Canadians that are suffering have access to treatments that are safe and proven to be effective," said James Price, the foundation's president and CEO.

原文出處

 附上 Regenetek Research Inc 所提供的 影片共三個病人的成功案例

 

 Study Subject: Linda Friesen

Study Subject: Deb O'Connell

Study Subject: Martine Millard 

不過也有不好的例子：

Lee Chuckry, 47, of Airdrie, Alta., said he spent $34,000 for the therapy only to find out his MS has worsened.

"I think it's just a big fraudulent scam," he told CBC News on Wednesday.
Chuckry, who has been battling MS for over a decade, said the treatment involved the widening of the veins in his neck — a practice advocates call liberation therapy — plus the injection of stem cells into his veins and spinal column.

Lee Chuckry of Airdrie, Alta., says he was recruited to undergo experimental stem cell therapy in India. After travelling there and spending $34,000 on the treatment, Chuckry says he believes his MS has worsened. (CBC)

 更多相關報導閱讀：

http://www.cbc.ca/news/canada/manitoba/ms-patients-question-credentials-of-winnipeg-man-involved-in-stem-cell-therapy-1.2901057

 小提醒：此為幹細胞於youtube上最新發現的影片(來自於病友的說法)為結合靜脈擴張+幹細胞注射的一種新型療法，還需要多加判別和注意。將會持續的追蹤.....

 

印度的幹細胞治療成果(成功案例)：幹細胞+Liberation治療(CCSVI)